MedPath

Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU

Phase 3
Completed
Conditions
Alcoholism
Interventions
Drug: PLACEBO
Drug: BACLOFEN
Registration Number
NCT02723383
Lead Sponsor
Nantes University Hospital
Brief Summary

Background: Alcohol is the leading psychoactive substance consumed in France, with about 15 million regular consumers. The National institute on Alcohol Abuse and Alcoholism (NIAAA) considers alcohol abuse to be more than 14 units of alcohol a week for men and 7 units for women. The specific complication of alcoholism is the alcohol withdrawal syndrome. Its incidence reaches up to 30% and its main complications are Delirium Tremens, restlessness, extended hospital stay, higher morbidity, psychiatric and cognitive impairment. Without appropriate treatment, Delirium Tremens can lead to death in up to 50% of patients.

Methods/Design: This prospective, randomised, controlled study versus placebo will be conducted in eighteen French intensive care units (ICU). Patients with an alcohol intake higher than the NIAAA threshold, under mechanical ventilation, will be included. The primary objective is to determine whether Baclofen is more efficient than placebo in preventing restlessness-related side effects in ICU. Secondary outcomes include mechanical ventilation duration, length of ICU stay, cumulative doses of sedatives and painkillers received within 28 days of ICU admission. Restlessness-related side effects are defined as unplanned extubation, Medical disposal removal, falling out of bed, ICU runaway, immobilisation device removal, self-aggression or towards medical staff. Daily doses of Baclofen/placebo will be guided by creatinine clearance assessment once a day.

Discussion: Restlessness in alcoholic patients is a life-threatening issue in ICUs. BACLOREA is a randomised study assessing the capacity of Baclofen to prevent agitation in mechanically-ventilated patients. Enrolment of 314 patients will begin in June 2016 and is expected to end in December 2019.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
314
Inclusion Criteria
  • Adults from 18 to 80 years old with an estimated alcohol intake of:

    • 14 units of alcohol per week during the month before hospitalisation for men aged 18 to 64
    • 7 units of alcohol per week during the month before hospitalisation for women or men older than 65.

AND Intubated, ventilated with an expected duration of mechanical ventilation> 24 hours at least

Read More
Exclusion Criteria
  • Hospitalization > 7 days
  • Baclofen administration before ICU admission (personal treatment or single administration)
  • Pregnancy
  • Porphyria
  • Burned on ICU admission
  • Personal treatment including Gamma-hydroxybutyric acid (Alcover/Xyrem)
  • Recent stroke or subarachnoid haemorrhage or head trauma with radiological evidence
  • Recent or old paraplegia or tetraplegia
  • Cardiac arrest with resuscitation manoeuvres before or after ICU admission
  • Contraindication to Enteral drug administration for longer than 24 hours
  • Lack of social protection
  • Hypersensitivity to Baclofen
  • Coeliac disease
  • Refractory epilepsy
  • Dementia, schizophrenia, Bipolar disorder or severe depression.
  • Parkinson's disease
  • Health care limitation owing to pejorative prognosis
  • Tracheotomy on ICU admission
  • Patients under guardianship or trusteeship
  • Patients already enrolled in interventional study
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PLACEBOPLACEBOpatient will receive placebo caps (lactose)
BACLOFENBACLOFENpatient will receive baclofen caps
Primary Outcome Measures
NameTimeMethod
Occurrence (yes or no) of agitation-related adverse eventsat the end of treatment (22 days max)

Occurrence (yes or no) of agitation-related adverse events during treatment/placebo administration with at least one sign out of the following:

* Unplanned extubation

* Medical disposal removal

* Falling out of bed

* ICU runaway

* Immobilization device removal

* Self-aggression or aggression towards medical staff.

Secondary Outcome Measures
NameTimeMethod
Extubation failure defined as reintubationwithin the next 48 hours after extubation
Riker Sedation -Agitation Scale (SAS) in the ICUwithin 28 days of ICU admission
Daily CIWA-Ar alcohol withdrawal scoreduring the week following extubation
Duration of mechanical ventilation during hospitalizationan average of 28 days
Length of ICU staywithin 90 days
Death during hospital stay during hospitalizationwithin 90 days
Number of adverse event (s) per patient occurring in ICU from Day 1 to Day 28until Day 28
Adverse event (yes or no) related to agitationwithin 28 days of ICU admission
Tracheotomy for failure of mechanical ventilation weaning during hospitalizationan average of 28 days
Ventilation free days (VFD)at day 28
Agitation requiring rapid intravenous or intramuscular administration of an hypnotic or neuroleptic (bolus)until Day 28
Reintubation due to restlessness or withdrawal syndromeuntil Day 28
Agitation and mortality in ICU at Day 28at Day 28
Infections acquired in the ICU: Urinary infection, pneumonia, catheter infection or bacteraemia during hospitalizationan average of 28 days
Total doses of sedatives and painkillers received in the ICUwithin 28 days of ICU admission
Length of total hospitalisationwithin 90 days
Death in ICUat days 28 and 90

Trial Locations

Locations (18)

CHU de Brest Réanimation Médicale

🇫🇷

Brest, France

Hopital Saint Antoine

🇫🇷

Paris, France

CHU de Caen Réanimation Médicale

🇫🇷

Caen, France

Chu Montpellier

🇫🇷

Montpellier, France

CHU NANTES - réanimation chirurgicale

🇫🇷

Nantes, France

CHD La Roche Sur YON

🇫🇷

La Roche Sur Yon, France

CH Le Mans

🇫🇷

Le Mans, France

CHU ANGERS - réanimation chirurgicale

🇫🇷

Angers, France

CHU de Brest Réanimation Chirurgicale

🇫🇷

Brest, France

Centre Hospitalier de Bretagne Sud Réanimation Polyvalente Lorient

🇫🇷

Lorient, France

CHU MONTPELLIER - Lapeyronie

🇫🇷

Montpellier, France

CHU NANTES -réanimation médicale

🇫🇷

Nantes, France

Chu Poitiers

🇫🇷

Poitiers, France

Ch Cornouaille

🇫🇷

Quimper, France

Chu Rennes

🇫🇷

Rennes, France

CHR Saint Nazaire

🇫🇷

Saint Nazaire, France

CHRU Tours Bretonneau

🇫🇷

Tours, France

Chu Tours

🇫🇷

Tours, France

© Copyright 2025. All Rights Reserved by MedPath